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1. Introduction
Iron is an essential trace element found in all cellular forms of life and plays a crucial role in
oxygen sensing and transport, electron transfer, and catalysis [1]. In ancient times, iron was
used in medicine for the treatment of the following diseases; alopecia, acne, vesicular bollus,
encrusting eruptions, erysipelas, paronychia, vaginal discharges, wounds, hemorrhoids, gout,
tuberculosis, diarrhea, perianal fistulas, excessive lacrimation, vomiting, weakness, edema,
fevers and cystitis [2]. Secondary iron overload in β-thalassemia patients is commonly caused
by increased dietary iron absorption and can be a result of multiple blood transfusions [3].
Consequently, the excessive active iron catalyzes the production of a variety of reactive oxygen
species (ROS), such as superoxide anions (O2•-), hydrogen peroxide (H2O2) and hydroxyl
radicals (HO•) via Haber-Weiss and Fenton reactions. The ROS is attributed to the function of
the metal in the redox cycle and can damage many cells and tissues including the heart, liver,
pancreas, erythrocytes and endocrine glands resulting in dysfunctions of the organs [4].
Hydrogen peroxide is normally applied to kill microorganisms in neutrophils; nevertheless,
an excess amount can be toxic.
β-Thalassemia patients suffer from ineffective erythropoiesis and require regular blood
transfusions to compensate for having chronic anemia. Transfused red blood cells (RBC) are
taken up and degraded by the reticuloendothelial system (RES) or tissue macrophages, leading
to a high accumulation of intracellular iron and saturation of plasma transferrin. The excess
iron appears in successive forms of toxic iron as a labile iron pool (LIP), and non-transferrin
bound iron (NTBI) and labile plasma iron (LPI) [5-7]. Effective iron chelators are required to
remove the toxic irons in order to prevent oxidative damage in the vital organs, particularly
the heart and liver. Iron chelators must be absorbed via the gastrointestinal tract into the blood
circulation and target tissues readily, and show minimal side effects. They should complex
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directly onto the plasma iron as well as the cellular iron; afterwards, the complexes can be
excreted from the body easily [8]. Serum oxidant activity in young β-thalassemia major patients
with iron overload is directly correlated with the serum ceruloplasmin and copper concentra‐
tions, and with serum iron (SI) concentration and total iron-binding capacity (TIBC), but not
with serum vitamin E concentration [9]. Levels of antioxidant enzymes such as superoxide
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) were greatly elevated in
the RBC of β-thalassemia minor patients to fight cellular increased oxidant and are close to
normal values in the RBC of β-thalassemia major patients due to the presence of transfused
normal RBC [10]. Levels of antioxidant compounds such as serum retinol (vitamin A),
carotenoids, α-tocopherol (vitamin E) were decreased in β-thalassemia major patients [11, 12].
Supplements of the antioxidant vitamins can prevent some of the damage in the thalassemic
RBC membrane. Thus, antioxidant therapy can be a supplemental medical regime to meliorate
pathophysiological complications and improve quality of life of thalassemia patients.
2. Iron overload in thalassemia patients
2.1. Causes of iron overload
Patients with β-thalassemia have a partial or complete lack of ability to synthesize the β-chains
of hemoglobin [13]. This process of β-globin chain synthesis is controlled by gene that is found
to be present in Chromosome 11. There are more than 200 points of mutation and rare deletions
of this gene. The production of the β-globin chain can range from near normal to completely
absent, leading to varying degrees of excess α-globins in the β-globin chain production. In the
β-thalassemia trait, the one gene defect is asymptomatic and results in microcytosis and mild
anemia. β-thalassemia major or Cooley anemia results from either severely reduced synthesis
or the absence of synthesis in both genes. If the synthesis of the beta chain is less severely
reduced, the person will have beta thalassemia intermedia. These persons experience symp‐
toms that are less severe and do not require lifelong transfusions to survive past the age of 20
years [14]. The amount of iron (20 - 30 mg) required for the daily production of 300 billion
RBCs is provided mostly by the iron that is recycled by the macrophages [6]. Importantly, iron
stored in the macrophages is safe and does not lead to oxidative damage [15]. Iron overload
can be caused by an increase in dietary iron absorption in hereditary hemochromatosis patients
[16] and by multiple blood transfusions in β-thalassemia patients. Duodenal iron absorption
in normal persons is approximately 1 – 2 mg/day and balanced with iron excretion at 1 – 2 mg/
day. Though thalassemia intermedia patients do not receive transfusions, abnormal iron
absorption produces an increase in the body’s iron burden evaluated to 2 – 5 g/year (3 - 9 mg
iron/day) [17]. Regular blood transfusions (420 ml/unit of donor blood equivalent to 200 mg
of iron) lead to double iron accumulation. Increased iron absorption along with multiple blood
transfusions in thalassemia patients can result in hemosiderosis, oxidative stress, hypercoa‐
gulability, liver inflammation, cardiomyopathy, endocrine dysfunctions and bone deformity,
of which the complications can be meliorated by many drugs and agents (Figure 1).
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Figure 1. Complications and treatments of thalassemia patients with iron overload
Consequently, iron overload and accumulation introduces progressive damage in the liver,
heart and in the endocrine glands. Plasma NTBI occurs in patients who have had multiple
blood transfusions. NTBI was originally identified in reference [18] for playing a major role in
the pathological conditions of iron overload. Circulating NTBI, as well as LPI, is detected
whenever the capacity of transferrin to incorporate iron is derived either from the GI tract or
when RES becomes a limiting factor. Both forms of toxic iron appear primarily in transfused
patients where the TIBC has been surpassed [19]. Pathologically, the NTBI fraction seems to
be translocated across the cell membrane irregularly, while the LPI is redox active and
susceptible to chelation [20]. Chronic iron overload has been attributed to highly elevated
levels of plasma iron and high accumulations of tissue iron. Excessive iron accumulation in
Antioxidants as Complementary Medication in Thalassemia
http://dx.doi.org/10.5772/57372
121
the vital organs is the cause of various liver diseases (e.g. hepatitis, hepatic fibrosis and
hepatocellular carcinoma), cardiomyopathies (e.g. cardiac arrhythmia and heart failure) and
endocrine gland dysfunction (e.g. diabetes, growth retardation, hypogonardism and hypo‐
parathyroidism) [21, 22].
2.2. Chemistry of catalytic iron
Iron acts as a cofactor within the active site of key enzymes in the biochemical pathways and
as a chemical catalyst in the unique redox activity. The iron can cycle between two oxidation
states, ferric ion [Fe(III) or Fe3+] and ferrous ion [Fe(II) or Fe2+], allowing it to act as an electron
donor and acceptor [23]. The biochemical functions of iron in vital cells are dependent on its
chemical properties. Limitation of iron bioavailability under aerobic conditions occurs when
the Fe2+ is rapidly oxidized in the solution to insoluble Fe3+ at physiological pH [Kfree Fe(III) =
10−18 M] [24]. Fe(III) iron is the most stable state of the biological complexes at physiological
oxygen concentrations. Many complexes of iron and biomolecules (protein or simpler mole‐
cules) are involved with reduction potential or redox potential (Eh). The Eh of complexed iron
in the range of a biological oxidant is +820 mV to the reductant at −320 mV, the redox reactions
are reversible whereas the reaction may be irreversible for the iron complexes when the
reduction potential occurs outside this range [1].
Iron  is  a  crucial  enzyme  cofactor  that  acts  in  the  reduction-oxidation  reaction  in  the
metabolism in the cells. Of outstanding interest, iron deposition in the heart cells can lead
to oxidative stress and cellular damage [25-27]. Heart failure is the leading cause of death
among  hemosiderotic  β-thalassemia  patients,  of  whom,  around  60%  die  of  this  cardiac
failure [28-30]. The importance of metals to both enzymatic reactions and oxidative stress
makes  them  the  key  players  in  mitochondria.  Mitochondria  are  the  primary  energy-
generating organelles  of  the cells  that  produce ATP through a chain of  enzymatic  com‐
plexes that require cytochromes iron and sulfur-iron, and are highly sensitive to oxidative
damage.  Moreover,  the  heart  is  one  of  the  most  mitochondria-rich  tissues  in  the  body,
making metals of particular importance to cardiac function [31]. In cardiac cells, excess iron
may result in oxidative stress and an alteration of myocardial function because of the DNA
damage that is caused by hydrogen peroxide through the Fenton reaction [6, 32]. Harm‐
ful  effects  of  iron  overload  on  the  hearts  of  patients  with  β-thalassemia  major  can  be
monitored  [25,  33-38]  and  treatment  with  effective  iron  chelators  can  protect  these  pa‐
tients from cardiac arrhythmia [39, 40]. Iron catalyzes the production of ROS including O2•-,
H2O2 and •OH via Haber-Weiss and Fenton reactions (Figure 2).
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Figure 2. Hydroxyl radical formation in metals-catalyzed Haber-Weiss and Fenton reactions [41]
Pharmacology and Nutritional Intervention in the Treatment of Disease122
Another Fenton reagent can be hemichromes, which are a family of denatured methemoglo‐
bins [42]. Hydroxyl radicals might be most harmful to lipid, protein and DNA, which are the
essential cell components (Figure 3). The •OH-induced membrane damage can be related
directly to a membrane-associated Fenton reagent [43]. Oxidative cell damage has been
attributed to the emergence of excessive levels of LPI that promote the production of ROS to
a level that exceeds the cellular defense capacity [44].
Figure 3. Production and harmfulness of ROS (Reprinted with modification from [45])
In β-thalassemia major patients, an outpouring of catabolic iron overwhelms the capacity of
iron-transporting protein transferrin, and generates NTBI and redox-active LPI in the plasma
compartment. Cytosolic LIP has been shown to be comprised of transitory Fe (II) and Fe (III)
forms which are possibly mediated by specific cellular iron reductases [20, 44]. In sub-cellular
organelles, mitochondrial iron serves in the formation of protein iron-sulfur clusters and
porphyrins. Additionally, endosomal iron provides the translocation of the endocytosed iron
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into cytosol or mitochondria, while lysosomal iron is associated with the products of iron-
protein degradation [46, 47]. LIP is a source of chelatable and redox-active transient iron in the
cells that serves as a crossroads of the cellular iron metabolism. The nature of the LIP has been
revealed by its capacity to promote ROS generation in its “rise and fall” patterns. LIP plays a
role as a self-regulatory pool that is sensed by cytosolic iron-regulatory proteins (IRP) and its
feedback is regulated by an IRP-dependent expression of iron import and storage. The LIP can
also be modulated by biochemical mechanism that override the IRP regulatory loops and
contributes to basic cellular functions.
2.3. Oxidative stress in thalassemia patients
In one study, β-thalassemia children were found to have elevated levels of thiobarbituric acid
reactive substances (TBARS), NAD(P)H oxidase (NOX) and SOD activity. Additionally, they
were found to have decreased levels of CAT activity and reduced glutathione (GSH) concentra‐
tion, along with unchanged GPx activity in their plasma compared to the plasma of the controls’
[48]. Seminal SOD and CAT activities of homozygous β-thalassemic patients with iron overload
were increased, probably due to a compensatory reaction to the persistence of high levels of
ROS. Increased seminal lipid peroxidation could have contributed to the impairment of sperm
motility [49]. Erythrocyte free reactive (non-heme) iron was significantly higher in β-thalasse‐
mia patients with HbE (30% >controls), which was associated with a high level of serum TBARS
(86% >controls) [50]. Elevated serum ferritin showed a positive correlation with elevated levels
of such liver enzymes as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and
alkaline phosphatase (ALP), but not γ-glutamyl transferase (GGT), confirming hepatic iron
overload. Serum ferritin also showed a positive correlation with elevated levels of plasma
TBARS and SOD. Plasma TBARS concentrations were increased in patients with α-thalasse‐
mia trait, and increased to the highest level in Hb H disease patient. Plasma levels of vitamin
A, C, and E were significantly decreased in α- and β-thalassemia patients [51, 52]. In addition,
their RBC revealed lower levels of vitamin E, GSH, CAT and SOD [51].
Isolated Hb chains can behave as pro-oxidants that can trigger oxidation of low-density
lipoprotein (LDL). Importantly, the descending order of the different Hb chains to the relative
oxidation of LDL protein, Apoprotein B (ApoB) and lipid parts was: α-globin chains > β-globin
chains > HbA. This indicates that the extracellular globin chains may be the trigger of the
lipoprotein alterations observed in β-thalassemia patients [53] and suggests that iron overload
should be involved in the oxidative stress shown in the cells [54]. In comparison with apopro‐
tein E2 (apoE2) and apoprotein E3 (apoE3) apoprotein E4 (apoE4) is considered the least
efficient under conditions of oxidative stress in thalassemia patients and this imples that apoE4
is a genetic risk factor for left venticular dysfunction [55]. Mean triglyceride concentrations
were not significantly different between thalassemia patients and the controls. Total choles‐
terol and LDL-cholesterol concentrations were found to be lower in β-thalassemia major and
thalassemia intermediate patients than in the controls (p <0.001), while HDL-cholesterol
concentrations were lower in thalassemia intermediate patients (p <0.03) [56]. This may account
for increased erythropoiesis and cholesterol consumption in thalassemia intermediate
patients, and iron overload and oxidative stress in β-thalassemia major patients. A previous
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revision suggested that iron-induced free radical formation in thalassemia patients might lead
to lipid peroxidation, LDL oxidation, stimulation of apoptosis and other damaging processes.
The essence in the chelating and antioxidant treatments of thalassemia patients has to be
considered within the context of free radical damage and its prevention [57].
Afanas'ev identified the major routes of superoxide damaging effects in the mitochondria.
These include initiation of apoptosis through a reduction of cytochrome c, activation of
uncoupled proteins by superoxide and a competition between superoxide and nitric oxide at
the Complex IV site (or cytochrome oxidase). The author suggests an application of effective
free radicals scavengers (rutin and flavonoids) for the treatment of thalassemic patients [58,
59]. From a comprehensive study in Indonesia, non-transfused thalassemia intermedia
patients showed mild signs of oxidative stress and increased hemoglobin degradation, but
revealed no significant indication of tissue or cell damage. Transfusion-dependent β-thalas‐
semia major patients showed a highly significant decrease in antioxidants and thiols, and a
tremendous iron overload along with cell damage. This situation was made even worse in
long-term transfused patients [60]. ROS and lipid peroxidation were found to be higher, and
GSH lower, in thalassemic RBC compared with normal RBC at the baseline as well as following
the hydrogen peroxide treatment. These effects were reversed by treatment with antioxidative
N-acetylcysteine (NAC) [61]. Platelets obtained from β-thalassemia patients contained higher
ROS and lower GSH contents than those from normal donors, indicating a state of oxidative
stress. Exposure of platelets to oxidants such as hydrogen peroxide and tert-butylhydroper‐
oxide, or to the platelet activators (e.g. thrombin), ionophore (e.g. valinomycin) or phorbol
myristyl acetate (PMA), stimulated the platelets' oxidative stress. Iron, hemin and thalassemic
RBC also stimulated the platelets' oxidative stress. Therefore, oxidative stress of the platelets
can lead to the activation of thromboembolic events [62]. Basal ROS level expressed as mean
fluorescent intensity (FI) was higher in thalassemia polymorphonuclear cells (PMN) (FI =
95.6±19.8) than in normal PMN (FI = 12.7±4.5). Treatment of thalassemia PMN with PMA
markedly increased the basal ROS level; in comparison, treatment with antioxidants, such as
NAC, vitamins C and vitamin E, reduced their basal ROS but enhanced their PMA response.
Administration of effective antioxidants may compromise their antibacterial capacity and give
prophylaxis for recurrent infections [63].
DNA damage can be caused by iron-induced free radicals in thalassemia patients. Lympho‐
cytes from a normal female did not respond to ferric chloride or hemosiderin, but did to ferrous
chloride and ferrous sulphate. Comparatively, lymphocytes from an Australian patient with
Hb S/β-thalassemia (double heterozygote-sickle phenotype) were more sensitive to ferrous
sulphate treatment. Interestingly, desferrioxamine (DFO) and deferiprone (DFP) reduced the
response [64]. Erythrocyte GPx activity was significantly lower in non-chelated β-thalassemia
major patients than those chelated with either DFO or DFP [65]. β-Thalassemia major patients
were deficient in vitamin A, C, D, B and folic acid [66]. Levels of ceruloplasmin concentra‐
tions and its ferroxidase activity were significantly higher in the thalassemia patients than in
the healthy controls. Interestingly, the levels were significantly higher in thalassemia patients
with Hp2-2 phenotype than in patients with other phenotypes, suggesting that thalassemia
patients with Hp 2-2 phenotype are under greater iron-driven oxidative stress [67]. Reduc‐
tion of delta-aminolevulinic acid synthase (δ-ALA) activity and an increase of peroxiredox‐
in-2  expression in  thalassemic  erythroid cells  might  represent  two novel  stress-response
protective systems [68].
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2.4. Iron chelation therapy
Nowadays, DFO, DFP and deferasirox (DFX) are iron chelators of choice used for the treatment
of β-thalassemia patients with iron overload. Their chemical structures are shown in Figure
4 [69-72]. DFO (Desferal®) is the first drug that was introduced in the 1970s to treat iron
overload. The hexadentate chelator has an extremely high affinity for iron (III) (DFO : Fe = 1:1,
Ka =1029) and a much lower affinity for other metal ions, such as zinc, calcium and magnesium
[73]. DFO is poorly absorbed from the GI tract and rapidly excreted in the urine (plasma half-
life of 5 - 10 minutes), it must be therefore administered parenterally; intravenously (iv),
intramuscularly (im) or subcutaneously (sc) [8, 74]. However, the drug exhibits side effects
including an elevated body iron burden, serious neurotoxicity and abnormalities of cartilage
formation [75-78]. DFP (L1 or Ferriprox®), a synthetic bidentate chelator, has been the first
orally active drug available for clinical use. A previous study demonstrated DFP decreased
serum ferritin and liver iron concentrations in transfusion-dependent thalassemia patients
[79]. Using magnetic resonance imaging (MRI) technique, DFP was able to reduce cardiac iron
overload and improve cardiac function more effectively when compared to patients treated
with DFO [80]. Recently, the Government Pharmaceutical Organization (GPO) of Thailand has
manufactured and launched domestically produced DFP product (GPO-L-One®) for the
treatment of Thai thalassemia patients with iron overload. This will make the in-house DFP
cheaper and more available than the imported DFP. However, its side effects include nausea,
vomiting, gastrointestinal disturbance, leucopenia and thrombocytopenia and zinc deficiency,
as they are typically observed these side effects are being evaluated in the patients [81, 82].
DFX (ICL670 or Exjade®), a tridentate oral chelator with a high affinity and specificity for iron,
has been clinically used for the treatment of transfusion-dependent thalassemia patients since
2003 [83-85]. Efficacy and safety of DFX uses have previously been evaluated and reported [83,
84, 86-88]. Common side effects of DFX are abdominal symptoms (usually diarrhea), skin
exanthems, elevated serum creatinine levels and renal tubular dysfunction [70].
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Figure 4. Chemical structures of DFO, DFP and DFX (Redrawn with modification from [89])
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In the medical regimen, DFO must be subcutaneously infused in β-thalassemia patients for
extensive periods in order to achieve a negative iron balance, ranging from 8 to 12 hours, five
to seven times per week, and at a daily dosage of 20 to 60 mg/kg body weight [72]. The patients
experienced pain and swelling at the injection site, cumulatively leading to poor patient
compliance [89, 90]. DFO chelation along with DFP or DFX has been designed to improve the
efficacy and to diminish the adverse effects in the treated patients [91, 92]. Ideally, the iron
chelator should be orally active, cheap and highly specific for iron, but not for other metal ions,
and should freely penetrate into the target tissues, so as to get the patients compliant and show
minimal side effects. Chelators can act upon different iron pools, including transferrin-bound
iron (TBI), NTBI and LPI in plasma compartment, and LIP in cytoplasm to form iron-chelate(s)
which will then be excreted in the urine and feces [8]. Clinical efficacy of chelation therapy has
been evaluated at different periods of time, generally by following up the levels of the
biochemical markers, including ferritin, total iron, TIBC, transferrin saturation, NTBI and LPI
in plasma with colorimetry [93, 94], and of tissue biopsied iron with pathological examination
(Perl’s staining), as well as in organ iron with a semi-quantum uncoupled inductive device
(SQUID) and magnetic resonance imaging (MRI) techniques [95-98]. Encompassing forms of
plasma NTBI are readily chelated by effective iron chelators [19]. However, the pathologically
relevant fraction of NTBI is that which is seemingly translocated across cell membranes in a
non-regulated manner and leads to excessive iron accumulation in the liver, heart, pancreas
and endocrine organs [20]. The LPI fraction is not only an accessible diagnostic marker of iron
overload and cell toxicity, but also a clinical parameter for assessing the mode and efficacy of
chelation therapy.
3. Antioxidants
Antioxidants can be defined as compounds that inhibit or delay, but do not completely prevent
oxidation. There are two basic categories of antioxidants, namely synthetic and natural
antioxidants.
3.1. Synthetic antioxidants
Mostly, the synthetic antioxidants that are widely used are phenolic compounds; for example,
butylated hydroxyanisole, butylated hydroxytoluene, tertiary-butylhydroquinone and gallic
acid (GA) derivatives.
3.2. Natural antioxidants
Natural antioxidants are found to be present in many sources such as plants, fungi, microor‐
ganism and even animal tissues. Phenolic compounds are also the majority group of natural
antioxidants. The three important groups of antioxidant are tocopherols, flavonoids and
phenolic acid. Natural antioxidants have been widely used in complementary and alternative
medicines; in comparison, the synthetic antioxidants have reported signs of toxicological
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evidence and caution should be imposed in their use. Most importantly, some natural
antioxidants are more potent, efficiency and safer than synthetic antioxidants.
Synthetic antioxidant Natural antioxidant
Inexpensive Expensive
Widely applied Use restricted to some products
Medium to high antioxidant activity Wide-ranging antioxidant activity
Increasing safety concerns Perceived as innocuous substances
Use banned in some cases Increasing use and expanding application
Low water solubility Broad range of solubility
Decreasing interest Increasing interest
Table 1. Advantage and disadvantage of natural and synthetic antioxidants.
Advantages and disadvantages of the antioxidants are mentioned in Table 1. Most natural
antioxidants are obtained in the diet from natural sources, especially from food of plant origin.
Vegetables, fruits, and other foodstuffs are the best sources of these natural antioxidants. These
antioxidants include vitamin C, vitamin E, carotenoids and polyphenol compounds. Antiox‐
idants that are derived from natural sources are preferred by consumers. This is due to
concerns over the toxic and carcinogenic effects of the synthetic antioxidants. Phenolic
compounds include a large class of phytochemicals with interesting biological properties.
Recently, the roles of these natural compounds in counteracting the negative effects of
ROS/RNS and maintaining the redox homeostasis of biological fluids have been reported.
Commonly, antioxidants can neutralize potentially harmful ROS in the cells before they induce
lipid and proteins oxidation. Antioxidants from plants are believed to be useful in preventing
aging, atherosclerosis, cancer, peptic ulcer, liver diseases and other degenerative pathologies,
such as cancer, diabetes, Alzheimer’s and Parkinson’s diseases.
Antioxidants are any substances that significantly delay or inhibit oxidation of the oxidized
substrate. These can greatly reduce the adverse damage to oxidants by crumbling or scaveng‐
ing free radicals before they react with biological targets such as biomolecules, subcellular
organelles, cells and tissues. The defense systems against the damage induced by ROS/reactive
nitrogen species (RNS) fall into three categories: 1) preventive antioxidants that suppress free
radical formation, 2) radical-scavenging antioxidants that inhibit initiation of chain reactions
and intercept chain propagation and repair processes, and 3) adaptation to generate and
transfer appropriate antioxidant enzymes. The hydrophilic antioxidants include vitamin C,
uric acid, bilirubin, albumin, and the lipophilic antioxidants include vitamin E, ubiquinol and
carotenoids. The radicals-scavenging antioxidant is described as a primary antioxidant, such
as flavonoids and vitamin E (α-tocopherol), and the others that do not involve direct scavenge
radical are secondary antioxidants.
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4. Potential antioxidants for use in thalassemias
Oxidative stress is not only a simple imbalance between the production and scavenging of
ROS, but also a dysfunction of the enzymes involved in ROS production. Dysfunction of NOX,
uncoupling endothelial nitric oxide synthase (eNOS), activation of xanthine oxidase (XO) and
dysfunction of the mitochondria are underlying signs of oxidative stress; therefore, NOX is
one of important therapeutic targets [99]. Pharmacological agents and approaches, as shown
in Figure 5, can be implemented to relieve oxidative stress by the following mechanisms.
1) Inhibition of NAD(P)H oxidase activity:
1.1) Apocynin (methoxy-substituted catechol) is a natural compound that has a structure
related to vanillin and exhibits anti-inflammatory activity, blocks an assembly of p47phox onto
membrane complex, decreases production of superoxide, enhances production of nitric oxide
and disrupts active NOX complex [100].
1.2) Chimeric peptides, such as polyethylene glycol-superoxide and NOX inhibitory peptide
(gp91dstat), can inhibit association of p47phox with gp91phox [101] and synthesis of Angiotensin
converting enzyme II (ACE-II) a dipeptidyl carboxy-peptidase that generates the vasocon‐
stricting peptide angiotensin II [102].
1.3)  Compound S17834 (e.g.  benzo(b)pyran-4-one)  inhibits  NOX activity  and superoxide
radical production and attenuates atherosclerotic lesions in apolipoprotein-E-deficient mice
[103].
1.4)  Statins  (e.g.  simvastatin)  are  hydroxymethylglutaryl  CoA  (HMG  CoA)  reductase
inhibitor hypocholesterolemic drugs that can prevent production of hydrogen peroxide and
superoxide  radicals,  interfere  with  the  renin-angiotensin-aldosterone  system,  and inhibit
NOX activation and expression [99]. Currently, Zacharski and colleagues have demonstrat‐
ed that statins increased HDL/LDL ratios and reduced serum ferritin levels in subjects with
advanced peripheral arterial disease. The results imply that statins may improve cardiovas‐
cular disease (CVD) outcomes, possibly by countering the pro-inflammatory effects of excess
iron stores [104].
1.5) ACE-II inhibitors (e.g. captopril, enalapril and quinapril) may act as antioxidants and
down-regulate the vascular NOX system. Angiotensin II, through Angiotensin I (AT1) receptor
activation, can induce vasoconstriction, cell growth, actions of pro-inflammatory cytokines
and profibrogenic agents, and the production of vascular ROS, such as superoxide radicals
[105]. Hence, the ACE-II inhibitors would lower ROS production and prevent vascular and
renal changes.
1.6) AT1 receptor antagonists (e.g. candesartan, losartan and irbesartan) reduce the expression
of NOX enzyme components, resulting in lower superoxide levels and increased nitric oxide
bioavailability in rat blood vessels [106].
1.7) Other blockers including calcium channel blocker (e.g. amlodipine, nifedipine and
dihydropyridine), β-blocker (e.g. metoprolol, propranolol and nebivolol) and α-receptor
blocker (e.g. doxazosin) can inhibit or interfere with functions of NOX activity [106, 107].
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2) Vitamins and dietary antioxidants (e.g. vitamin C, vitamin E, β-carotene, polyphenols,
flavonoids, olive oil and nuts) can decrease the oxidation of LDL (bad cholesterol), improve
vascular endothelial functions, enhance NOS activity and attenuate NOX activity in rat aorta.
3) L-Arginine is a nitric oxide generator that can improve vascular function and regulate NOS
expression and synthesis.
4) Thiol-containing compounds (e.g. α-lipoic acid and NAC) potentially inhibit LDL oxidation,
decrease oxidative stress, and attenuate hypertension, insulin resistance and oxidative stress.
5) Estrogen and hormone replacement therapy can reduce the morbidity and mortality
associated with CVD, lower production of superoxide radicals, up-regulate NOS gene
expression, activate cyclo-oxygenase (COX) gene and reduce the production of vasoconstrictor
endothelin.
6) Cu/Zn SOD (MW = 31 kD) mimetics are selective synthetic compounds; for example, M40401
(MW = 483), M40403 (MW = 501), SC-55858, that either inhibit their formation or remove
superoxide anion [108].
7) Xanthine oxidase inhibitors (e.g. oxypurinol and allopurinol) improve endothelial function
in hypercholesterolemic subjects, type II diabetic mellitus (DM) patients, congestive heart
failure (CHF) and cigarette smokers.
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Figure 5. Drugs used for therapeutic purposes exhibits antioxidant activity
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5. Benefits of antioxidants in thalassemia patients
5.1. Administration in thalassemia patients
β-Thalassemia major patients who suffered from leg ulcers and were treated with ascorbic acid
(3 g/day) for eight weeks showed a high rate of either complete or partial healing [109].
Improvement of ulcer healing in β-thalassemia major patients was observed when they were
orally administered with pentoxifylline (1.2 g/day) which is xanthine derivative and functions
as a competitive non-selective phosphodiesterase inhibitor [110]. Plasma antioxidant enzyme
activity and selenium concentration increased in subjects with the Hb Lepore trait and were
found to be significantly low in those patients with the α-thalassemia trait, while erythrocyte
Se content was significantly increased in α-thalassemia patients [111]. N-allylsecoboldine may
act as an effective antioxidant and protect cells against oxidative damage in β-thalassemic red
blood cells [112]. Plasma vitamin E levels were lower in β-thalassemia intermedia patients
compared to the controls and these levels were positively correlated with vitamin E in the LDL
[113]. Treatment of the patients with vitamin E (600 mg/day, orally) for nine months improved
the antioxidant/oxidant balance in the plasma, LDL particles and red blood cells, and coun‐
teracted the lipid peroxidation processes [114].
Significant decrease of GSH and proliferation in peripheral blood mononuclear cells (PBMC)
were found in β-thalassemia major patients, probably due to the abnormality of cell mediated
immunity (CMI) under iron overload conditions. Treatment of the patients with silymarin,
which is an extract of milk thistle seed containing anti-hepatotoxic silibinin, led to a restoration
of the GSH levels and PBMC proliferation, suggesting antioxidant and immunostimulatory
activities and the benefits of using flavonoids to normalize immune dysfunction in β-thalas‐
semia major patients [115]. In vitro treatment of blood cells from β-thalassemia patients with
N-acetylcysteine amide (AD4), NAC and vitamin C increased the reduced GSH content of RBC,
platelets and PMN leukocytes, and reduced their ROS. Intra-peritoneal injection of AD4 to β-
thalassemic mice (150 mg/kg) reduced the parameters of oxidative stress (p <0.001). These may
imply the superiority of AD4, compared to NAC, in reducing oxidative stress markers in
thalassemic cells, both in vitro and in vivo, and also providing a significant reduced sensitivity
of thalassemic RBC to hemolysis and phagocytosis by macrophages [116]. In vitro treatment
of blood cells from β-thalassemia patients with fermented papaya preparation (FPP) increased
the GSH content in the RBC, platelets and PMN leukocytes, and reduced their ROS, membrane
lipid peroxidation and phosphatidylserine (PS) externalization. Importantly, oral administra‐
tion of FPP to β-thalassemia mice (50 mg/mouse/day for 3 months) and to thalassemia patients
(3 g x 3 times/day for 3 months) reduced the levels of the oxidative stress parameters signifi‐
cantly. Suggestively, the FFP would be beneficial in reducing thalassemic RBC sensitivity to
hemolysis and phagocytosis by macrophages, improving PMN ability to generate the oxida‐
tive burst and to reduce the platelet tendency to undergo activation [117].
Treatment of thalassemic RBC with erythropoietin (Epo) increased their GSH content and
reduced their ROS, membrane lipid hydroperoxides, and PS exposure. Injection of Epo into
heterozygous β-thalassemia mice reduced the oxidative markers. Probably, Epo might likely
be an antioxidant that can alleviate symptoms of hemolytic anemia and reduced susceptibility
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of RBC to undergo hemolysis and phagocytosis [118]. Thalassemic lymphocytes exhibited
approximately a two-fold increase in the sensitivity to treatment of food mutagen/carcinogen,
3-amino-1-methyl-5H-pyrido(4,3-b)indole (or Trp-P-2) in vitro. However, treatment with
flavonoids (quercetin and kaempferol) reduced the responses to Trp-P-2 to untreated control
levels, significantly [119]. Transfusion-dependent thalassaemia patients were vitamin E
deficient (0.45±0.21 mg/dl in all patients, 0.43±0.19 mg/dl in splenectomized patients), when
compared to healthy subjects (0.76±0.22 mg/dl). Replacement therapy with vitamin E is
necessary to correct its low serum levels easily (0.36±0.13 mg/dl before therapy and 1.19±0.35
mg/dl after therapy) [120]. Paraoxonase (PON) and arylesterase activities were significantly
lower in β-thalassemia major patients than in the control healthy subjects, whereas total
oxidant status, total peroxide concentration levels, and the oxidative stress index were
significantly higher in the patients than in the controls in reference [121]. In addition, the
activity of prolidase, a hydrolytic enzyme involved in collagen degradation was significantly
increased in β-thalassemia major patients (53.7±8.7 U/l) compared to the control group
(49.2±7.2 U/l). Total oxidant status was significantly increased in the patients (5.31±3.14 mmol
H2O2 equivalent/l) compared to the controls (3.49±2.98 μmol H2O2 equivalent/l). Oxidative
stress index was significantly increased in the patients (3.86±3.28 arbitrary unit) compared to
the controls (2.53±2.70 arbitrary unit), while antioxidant capacity expressed as TEAC (1.61±0.30
μM) in the patients’ plasma and this was not significantly different from that (1.64±0.33 μM)
of the controls’ plasma [122]. Administration of lipophilic antioxidant vitamin E (10
mg/kg/day for 4 weeks) is beneficial in the management of transfusion-dependant β-thalas‐
semia HbE patients [123]. A current study has demonstrated that levels of iron parameters,
such as serum ferritin, NTBI and transferrin receptors, were significantly increased in β-
thalassemia major and thalassemia intermedia patients, compared to the controls and in severe
cases when compared to the mild cases. Levels of serum ferritin, MDA, NTBI and GSSG/GSH
were significantly increased in thalassemia intermedia patients; activities of serum glutathione
reductase (GR), GPx and SOD were significantly reduced in these patients; while serum
ascorbic acid concentrations were mildly reduced in the patients [124]. Interestingly, DFP has
been reported to be a potent pharmaceutical antioxidant [125].
Patients with Hb H disease, β-thalassemia/Hb E and β-thalassemia major had vitamin E
deficiency; however, supplements of vitamin E and selenium to the patients prevented RBC
oxidation and increased RBC resistance to oxidative damage [126, 127]. There were no
significant differences in the mean serum vitamin A, E concentrations and the vitamin E/
cholesterol ratio between pregnant women with normal hemoglobin and hemoglobinopathies
(Hb E and thalassemia) [128]. Patients with β0-thalassemia/Hb E disease with lower blood Hb
concentration had significantly higher erythrocyte SOD activity and the Hb concentrations
were inversely correlated with the SOD activities (p <0.001) [129]. Supplementation of vitamin
C plus vitamin E has greater benefits than vitamin E alone in promoting antioxidant status
[130]. Administration of CoQ10 (100 mg/day) for six months markedly increased activities of
plasma SOD, CAT and GPx, and decreased plasma MDA concentration of β-thalassemia HbE
patients [131]. Increased oxidative stress in β-thalassemia/Hb E patients relates to higher levels
of MDA, SOD and GPx in RBC, serum NTBI, and lower level of RBC GSH.
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5.2. Intervention of antioxidants in β-knockout (BKO) thalassemia mice
Nowadays, all clinical trials in humans and animals need to be approved by highly experienced
ethical committees. Accurate animal models that recapitulate the phenotype and genotype of
patients with β-thalassemia would enable researchers to develop possible therapeutic ap‐
proaches. In this case thalassemic mice have been developed by groups of researchers
[132-135]. The Thalassemia Research Center at Mahidol University, Salaya Campus in
collaboration with the Murdoch Children Research Institute Melbourne, Australia have inbred
wild type (WT) C57BL/6, β-knock (BKO) thalassemia (Hbβth-3/Hbβ+), β-thalasssemia/HbE
(LCRεGγAγδβE) Hbβ+/Hbβ+) (HT HbE), double heterozygous (LCRεGγAγδβE) Hbβ+/Hbβth-3)
(DH) and rescued β-thalassemia Hb E (LCRεGγAγδβE) Hbβ0/Hbβ0) (rescued β/HbE) mice in
order to investigate the properties of the potential antioxidants and iron-chelating agents.
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Figure 6. Iron deposition in the livers and spleens of the wild type (WT), transgenic (TG), β-knockout (BKO) thalasse‐
mia and double heterozygous (DH) thalassemia mice (S. Srichairatanakool, unpublished data)
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Having measured the amounts of tissue iron of the WT and thalassemia mice, the BKO mice
had the highest iron content accumulated in the livers and spleens when compared to the TG
mice and WT mice, which the splenic iron content was far higher than the liver iron content
(Figure 7). The results indicated that anemic conditions persisting in the BKO mice were similar
to β-thalassemia intermedia and enhanced an increase of duodenal iron absorption for
accelerating erythropoiesis. In our experimentations, feeding the BKO mice with a high iron
diet (such as iron ferrocene) can load iron into their blood and tissue compartments, leading
to iron overload and oxidative tissue damage. Their hematological parameters were deter‐
mined and are illustrated in Table 2 [136]. Most importantly, the BKO thalassemia mice were
found to be the most anemic when compared to the other types of thalassemia mice and their
phenotype mimiced the human thalassemia intermedia patients. The mice heterozygous for
deletion of the β-globin gene appear normal, but their hematologic indices show the charac‐
teristics that were typical of thalassemia intermedia. These include dramatically decreased
hematocrit (Hct), hemoglobin (Hb) and red blood cell counts [136]. Bone deformities and
splenic enlargement due to increased hematopoiesis [137], and iron overload in the vital organs
(e.g. spleen, liver and kidneys) were also found in the heterozygous β-thalassemic mice, in
reference [138].
Mice RBC(x106 cells/μl)
Hb
(g/dl)
Hct
(%)
MCV
(fl)
MCH
(pg)
RDW
(%)
Reticulocyte
(%)
ROS
(Mean FI)
PS cell
(%)
WT 8.37±0.54 13.35±0.85 39.32±3.22 46.95±1.41 15.96±0.48 12.64±1.25 3.88±0.74 7.51±3.85 1.06±0.56
HT Hb E 7.95±0.36 12.24±0.56 35.69±1.58 44.93±0.84 15.40±0.35 14.47±0.79 4.65±0.86 3.28±0.43 0.87±0.29
BKO 5.34±0.63 7.06±0.61 22.86±2.05 43.05±2.95 13.32±1.09 23.17±2.53 29.01±5.76 170.1±24.6 3.35±0.75
DH 8.32±0.51 12.81±1.09 38.55±3.15 46.34±2.33 15.41±0.96 14.15±1.16 3.64±1.70 13.86±2.98 1.07±0.35
Rescued β/
Hb E 8.87+0.87 11.08±1.17 38.02±3.54 42.93±2.06 12.52±0.51 20.03±1.43 15.12±3.33 117.4±67.2 1.24±0.72
Abbreviations: Hb = hemoglobin, Hct = hematocrit, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin,
RDW = RBC distribution width, ROS = reactive oxygen species, PS = phosphatidylserine.
Table 2. Hematological parameters (mean±SD) of erythrocyte WT and β-thalassemia mice (Redrawn from
Wannasuphaphol et al. [136]
5.2.1. Curcuminoids
Curcuminoids derived from Curcuma longa Linn. (turmeric) contained curcumin (diferuloyl‐
methane), demethoxycurcumin (p,p’-dihydroxyldicinnamoylmethane), as well as bis-deme‐
thoxycurcumin (p-hydroxylcinnamoylmethane), which curcumin was found to be the most
abundant and major active compound (Figure 7). Phenolic, methylene and β-diketo groups in
the curcumin molecule participated in antioxidant, iron-chelating, free radical-scavenging and
anti-lipid peroxidation activities.
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Figure 7. Chemical structures of curcumin, demethoxycurcumin and bis-demethoxycurcumin found in turmeric Curcu‐
ma longa Linn (Redrawn from http://www.molecular-cancer.com/18 September 2013)
Interestingly, curcumin can bind ferric and ferrous ions, in a concentration-dependent manner
and with a molar ratio of 1:1, to form a red colored complex with a predominant peak at 500
nm. The curcumin itself chelates biological iron (e.g. plasma NTBI) and can work with DFP in
lowering plasma NTBI levels more efficiently in vitro [139]. Curcuminoids effectively reduced
levels of plasma NTBI, and liver weight index, non-heme iron, plasma and liver MDA
concentrations, but increased the plasma GSH concentrations of iron-loaded BKO thalassemic
mice [138]. Our results of the atomic absorption spectrometric and Perl’s staining examinations
demonstrated that curcumin was able to decrease the accumulation of heart iron and to depress
heart rate variability of BKO mice with iron overload, suggesting the cardioprotective effect
of curcumin [140]. Treatment of β-thalassemia HbE patients with curcuminoids (Thailand GPO
product, 500 mg/day) for three months increased erythrocyte SOD as well as the GPx activities
and GSH concentrations, and lowered levels of plasma NTBI and platelet factor-3 like activity
[141, 142]. The same researcher group has been using a cocktail containing DFP, vitamin E,
NAC and the curcuminoids for treatment of the thalassemia patients and expected that the
treatment would improve their iron overload and oxidative stress more effectively (Kalpra‐
vidh and coworkers, personal communication). A recent study has reported that iron content
of HDL-2 and HDL-3 from β-thalassemia/HbE patients was higher while the cholesterol
content was lower than those levels found in the healthy subjects. Thalassemic HDL-2 and
HDL-3 had increased levels of conjugated diene, lipid hydroperoxide and TBARS. The
thalassemic HDL had lower peroxidase activity than the control HDL and could not protect
against CuSO4-induced oxidation of LDL [143].
5.2.2. Tea
Recently, the demand for green tea has increased due to current trends in human health
concerns and preference. The main components found in green tea are polysaccharides,
flavonoids, vitamins B, C, E, γ-aminobutyric acid, catechin compounds and fluoride. Among
them, catechin compounds have been of focus for their strong antioxidant capacity. The
pharmaceutical activities of the components have been studied. Tea (Camellia sinensis) is an
excellent source of polyphenols, namely catechins, including (-)-epicatechin (EC), (-)-epicate‐
chin 3-gallate (ECG), (-)-epigallocatechin (EGC), (-)-epigallocatechin 3-gallate (EGCG), (+)-
catechin (C) and (-)-gallocatechin (GC). Among them, EGCG exerted the strongest antioxidant
capacity and was found to be the most abundant, as well. It has been reported that catechins
possess free radical scavenging abilities and iron chelating properties [144]. Green tea also
showed a protective effect under various oxidative-related pathologic conditions.
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Figure 8. Chemical structures of catechins in tea (Camellia sinensis) (Redrawn from [145])
Drinking tea produced a 41 – 95% inhibition of dietary iron absorption in five β-thalassemia
major and one β-thalassemia intermedia cases, which the iron absorption increased strikingly
in the β-thalassemia intermedia cases, in references [146, 147]. Interestingly, Thai researchers
have elucidated that green tea extract (GTE) and EGCG fraction were able to decrease iron (as
NTBI) in plasma, eliminate plasma lipid-peroxidation product (as TBARS) and destroy the
formation of erythrocyte ROS in vitro [144, 148] and in iron-loaded rats [149]. In addition, the
GTE inhibited or delayed the deposition of hepatic iron in regularly iron-loaded BKO thalas‐
semic mice effectively. This implies a prevention of iron-induced ROS generation and conse‐
quently liver damage and fibrosis by green tea consumption [150]. Our group has found that
elevated levels of plasma NTBI and lipid peroxidation tended to be normalized in the BKO
mice in response to oral therapy with GTE, while their plasma GSH concentrations were also
increased by up to 2-times. The mice exhibited a decrease of the lipid peroxidation product
and an improvement in the oxidant–antioxidant balance in erythrocytes. Importantly, GTE
was effective in inhibiting hemolysis and thereby prolonged RBC half-life in the BKO mice
(Sakaewan Ounjaijean PhD thesis. Chiang Mai University; 2011). Our current study has shown
that the treatment of iron-loaded mouse hepatocytes and human hepatoma (HepG2) cells with
GTE (0 – 100 mg/dl) and EGCG (0 – 200 μM) removed intracellular LIP and ROS efficiently,
and relieved the mitochondrial membrane collapse, implying a hepatoprotective effect of
green tea catechins in the hepatocytes with iron overload [151].
5.2.3. Mango (Mangifera indica L.)
Mangoes can be considered a good source of dietary antioxidants, such as ascorbic acid,
carotenoids and phenolic compounds. β-carotene was found to be the most abundant carote‐
noid in several cultivars. The nutritional value of mango is that it is a source of vitamin C and
provitamin A. Mangiferin (1,3,6,7-tetrahydroxyxanthone-2-glucopyranoside) (Figure 9) can
interact with iron and other cations and also shows antioxidant activity by eliminating the
superoxide radical in vitro, in which 100 μM of mangiferin was equivalent to the activity of 1
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U/ml of SOD. This also revealed the pharmacologic effects modulating gene expression that
were related to the inflammatory response [152]. Mangiferin xanthone modulates the expres‐
sion of many genes critical for apoptosis regulation, viral replication, tumorigenesis, inflam‐
mation and autoimmune diseases, suggesting its possible value in the treatment of
inflammatory diseases and/or cancer [153]. Vimang mango peel extract with a high mangiferin
content acted as an antioxidant and complexed with Fe3+ efficiently, leading to protection of
iron-induced oxidative liver damage and DNA fragmentation [154, 155]. Hydrolysable
gallotannin present in mango kernels showed the inhibitory effects of bacterial growth, which
was probably due to their iron-complexing properties [156].
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Figure 9. Fresh mango and chemical structure of mangiferin (Redrawn from [157])
Kaew mango peel extract can chelate both Fe3+ and Fe2+ to form the products with different
predominant wavelengths, of which the binding was found to be dose-dependent and affinity-
different. The green peel extract tended to exhibit stronger iron-binding abilities than the ripe
peel extract and it is likely that the green peel might contain different kinds and amounts of
phytochemical ingredients (Figure 10).
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Figure 10. Iron-chelating activity of aqueous extract of Kaew mango peel (Srichairatanakool, S. unpublished data)
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As shown in Table 2, the degree of antioxidant activity of the mango peel extracts were found to
be Mahajanaka (ripe > green) > Chok-anan (green > ripe) > Namdocmai (green > ripe) > Kaew
(ripe ~ green). The antioxidant activities were well correlated with their total phenolic contents
and vitamin C concentrations. Incredibly, amounts of vitamin C in the extracts were lower than
those of the total phenolic compounds. Mangiferin contents in the peel extracts were very low.
Mango/Status Antioxidant activity(mg TEAC/g extract)
Total phenolics (mg
GAE/g extract)
Vitamin C
(mg/g extract)
Mangiferin
(mg/g extract)
Mahajanaka/Ripe 225.6±4.4 107.6±9.6 5.49±0.23 1.49±0.25
Mahajanaka/Green 114.3±7.4 44.8±5.9 0.96±0.07 0.57±0.10
Chok-Anan/Ripe 120.1±5.4 46.0±7.0 0.75±0.08 4.62±0.37
Chok-Anan/Green 192.4±4.5 85.7±7.7 4.22±0.22 6.80±0.06
Namdocmai/Ripe 102.9±4.9 49.7±8.5 0.69±0.03 0.25±0.01
Namdocmai/Green 33.1±2.6 5.3±0.8 0.27±0.091 0.25±0.01
Kaew/Ripe 63.2±0.2 34.8±0.7 ND 0.02
Kaew/Green 65.3±0.1 55.9±0.3 ND 0.43
ND = not determined.
Table 3. Antioxidant activity, total phenolics, vitamin C and mangiferin contents (mean±SD) in aqueous extracts from
ripe and green mango peels (Sricharatanakool, S. unpublished data)
5.2.4. Rice (Oryza sativa and Oryza glaberrima)
Rice is an economic cereal plant ±that is grown in many countries in Asian and Africa. Varieties
of Asian rice include Thai rice (O. sativa cv. indica), Indonesian rice (O. sativa cv. javanica) and
Japanese rice (O. sativa cv. japonica). Additionally, we have listed African rice (O. glaberrima).
Regarding its nutritional values, rice grain contains carbohydrates (e.g. amylose and amylo‐
pectin) and rice bran is abundant in inositol, inositol hexaphosphate (or phytate), oil, ferulic
acid, γ-oryzanol, phytosterol and tocotrienol. The ingredients in rice bran likely prevent
carcinogenesis, hyperlipidemia, fatty liver, gallstone disease and heart diseases [158]. Red and
purple rice bran possesses several fold higher hydrophilic and lipophilic anti-oxidative
phenolics and flavonoids (predominantly cyanidine-3-glycoside) levels than freeze-dried
blueberry and broccoli. Rice grass contains chlorophyll as a major ingredient and pheophytin
(or pheo) as the second most abundant component (Figure 11). Pheophytin is synthesized in
rice grass, spinach (Spinacia oleracea) leaves and Michelia alba leaves, but is not a degradation
product of chlorophyll [159], and the compound reveals a level of antioxidant activity that is
similar to that of ubiquinone [160].
Spinach pheophytin a (λmax 409 nm) and pheophytin b (λmax 435 nm) can chelate ferric ion and
produce the Fe-pheophytin a complex (λmax 393 nm) and Fe-pheophytin b complex (λmax 421
nm) [161]. Germinating rice grain synthesizes iron-chelating compounds, deoxymugineic acid
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and nicotinamine, and sequesters iron from the ground for their growth and development
[162]. Interestingly, wheat grass (WG) juice which has been used as a general-purpose health
tonic in Indian medicine and has shown at least a 25% reduction in the number of blood
transfusions needed in β-thalassemia major patients [163] and also increased their blood
hemoglobin levels [164]. Nonetheless, a contradictory report has shown that the oral admin‐
istration of WG juice tablets for one year was not effective in reducing blood transfusions in
transfusion-dependent β-thalassemia major patients [165].
Pimpilai and colleagues from Maejo University, Chiang Mai investigated the antioxidant
activity of the Thai black rice grass (TBRG), Thai red rice grass (TRRG) and Thai fragrant rice
grass (TFRG) extracts by using the TEAC colorimetric method and found that they exhibited
antioxidant properties. The extracts dose dependently bound Fe3+ (ferric NTA) and Fe2+
(ferrous citrate) and formed the complex(s) with maximal absorption values at 393, 378 and
580 nm, respectively (personal communication). HPLC analysis showed different amounts of
catechin derivatives as follows: 3.27 mg C, 4.51 mg EC and 5.19 mg EGCG in 1 g TBRG extract;
4.48 mg C, 6.22 mg EC and 5.23 mg EGCG in 1 g TRRG extract; and 5.89 mg C, 4.38 mg EC and
5.26 mg EGCG in 1 g TFRG extract. Currently, Pimpilai and Srichairatanakool have found that
feeding rice grass (Sukhothai 1) extract (100 mg/kg body weight) along with a high iron diet
to β-thalassemia mice for three months slightly increased their blood hemoglobin concentra‐
tions from 10.04±0.51 to 11.04±1.14 g/dl (unpublished data), while treatment with the extract
(0, 50 and 100 μg/ml) decreased levels of liver MDA (153.6±44.7, 102.9±22.4 and 102.4±58.0 μg/
mg tissue protein, respectively) and levels of labile iron (100±13, 120±1 and 125±5% fluorescent
intensity, respectively) in iron-loaded HepG2 cell cultures. Therefore, the rice grass extracts
would contain antioxidant compounds including chlorophyll, pheophytin and catechin
derivatives, of which the two latter may play important roles in iron chelation and anti-lipid
peroxidation to ameliorate oxidative tissue damage in the thalassemia cases with iron over‐
load. Consequently, rice grass extracts need to be clinically studied in thalassemia patients in
the near future.
6. Evaluation of oxidative stress and antioxidant status in thalassemias
Electron paramagnetic resonance (EPR) 'radical probe' was used to determine the total
oxidative status in patients affected by thalassemia, and to evaluate new strategies of chelation,
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Figure 11. Chemical structures of chlorophyll, pheophytin, iron-pheophytin complex and heme [161]
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new chelators, or the efficacy of antioxidant formulas [166, 167]. Raman spectroscopic techni‐
que has been developed for the monitoring of Raman hemoglobin bands to evaluate oxygen‐
ation capability, oxidative stress and deformities of thalassemic erythrocytes and to assess the
responses to drug therapies [168]. Consistent with the study, in reference [169], serum PON
activity and total antioxidant capacity were significantly lower in patients with the β-thalas‐
semia trait patients, MDA and carotid artery intima-media thickness were significantly higher
in β-thalassemia trait. The total antioxidant capacity, MDA, and CIMT levels were correlated
with serum PON1 (r = 0.945, -0.900, 0.940 and -0.922 respectively). Additionally, serum total
antioxidant capacity and MDA levels were well correlated (r = -0.979) [170].
An earlier study in 1986 showed that patients with Hb H diseases, including α-thalassemia 1
or α-thalassemia 2 and 21 with α-thalassemia 1/Hb Constant Spring, had increased activities
of erythrocyte SOD, GPx, and CAT when compared with those of the controls. The α-thalas‐
semia 1/Hb CS patients had higher SOD and GPx activities, but lower CAT activity than the
patients with α-thalassemia 1/2 [171, 172]. One year later, a study of oxidative stress and the
antioxidants in β-thalassemia/hemoglobin E patients in Thailand was conducted [173].
Significantly higher levels of urine N-acetyl-β-D-glycosaminidase, MDA and β2-microglobulin
along with aminoaciduria and proximal tubular abnormalities were found in pediatric α-
thalassemia patients (Hb H disease and HbS/CS), and this was possibly due to increased
oxidative stress [174]. A one-year treatment with DFP significantly decreased serum ferritin,
NTBI, and MDA (p <0.05) of transfusion-independent β-thalassemia/HbE patients. Mean
pulmonary arterial pressure and pulmonary vascular resistance were diminished significantly
(p <0.05). All those parameters were still improved after subgroup analysis was done for the
high ferritin group (>2500 ng/ml). The results imply that DFP therapy alone improved iron
overload and oxidative stress and the compliance was positive [175]. Oxidative stress was
increased in Thai HbE/β-thalassemia patients, as the blood GSH decreased, GSH/GSSG ratio
reduced markedly, superoxide anion released from blood cells elevated highly, and γ-
glutamylcysteine ligase activity was increased. Additionally, basal forearm blood flow was
significantly increased whereas forearm vasodilatory response to reactive hyperemia was
depressed [176].
When using ESR spectroscopic quantification of hemin, the serum hemin readily catalyzed
free radical reactions and it would be a major pro-oxidant in the blood circulation of β-
thalassemia Hb E patients [177]. A previous study showed a precipitous decrease in α-
tocopherol and increased TBARS concentrations in both plasma and lipoproteins obtained by
Thai β-thalassemia Hb E patients. Cholesteryl linoleate showed a reduction of 70% in LDL,
while other cholesterol ester levels showed a lower reduction. A good correlation of NTBI and
TBARS (p <0.01) in LDL strongly supported the contention that iron overload is responsible
for initiating the lipid peroxidation in thalassemia patients [178]. The ESR results demonstrated
a magnitude of increased lipid fluidity in thalassemic lipoproteins. Lipid fluidity at the LDL
and HDL cores showed a good correlation with the oxidative stress markers and the α-
tocopherol level, suggesting that the hydrophobic region of the thalassemic lipoprotein would
be a target site for oxidative damage [179]. Gas chromatography/mass spectrometric (GS/MS)
technique has been validated in quantifying ortho- and meta-tyrosine as biomarkers of protein
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oxidative damage in plasma samples of β-thalassemia patients [180]. Pumala et al. have found
that PON1 activity was significantly reduced in association with oxidative stress in the patients
with β-thalassemia hemoglobin E, and significant correlations were observed between HDL-
PON1 activity and oxidative stress markers (including plasma α-tocopherol and the ratio of
cholesteryl linoleate to cholesteryl oleate in HDL, and a marked increased platelet-activating
factor/acetylhydrolase (PAF-AH) activity [181]. The GC/MS-based assay showed that the level
of urinary and plasma lipid peroxidation poroduct, F(2)-isoprostane in the thalassemic group
was significantly increased [182]. An average antioxidant level in Thai thalassemia patients
with the HbE trait (3.276±0.209 mM TEAC) was significantly decreased (p = 0.008) when
compared to the healthy subjects (3.439±0.220 mM TEAC) [183]. It has been reported that Thai
thalassemia major patients are associated with an alteration of CYP2E1 and CYP3A4 activities
[184], but not CYP1A2 [185]. Anemia was not pronounced in the rescued mice (C57BL/6) with
the Hb E transgene mimicing the human β-thalassemia/HbE phenotype; nonetheless, other
hematologic parameters in their RBC include highly oxidative stress, no marked changes in
PS and vesicles, and a shortened life span, which were abnormally similar to the BKO
thalassemic RBC group [136].
7. Conclusions
Under iron overload, oxidative stress plays a major role in the pathophysiologic complications
of thalassemia patients. Free extracellular toxic iron (e.g. NTBI and LPI) and intracellular redox
iron (e.g. LIP and plasma membrane nonheme iron) that have been identified in thalassemic
blood and tissues are responsible for the generation of oxidative stress by catalyzing a
formation of oxygen radicals over the antioxidant capacity of the cells. Consequently, there is
a rationale to support iron chelation therapy for the elimination of the free-iron species and to
promote the free-radical scavenging activity of the antioxidants. Not only synthetic (vitamin
C, vitamin E and NAC) but natural (e.g. polyphenolics, flavonoids and fish oils) antioxidants
are also capable of ameliorating such increased levels of oxidative stress. Taken together with
an effective iron chelator, antioxidants may provide a substantial improvement in hemolytic
anemia cases, and particularly in thalassemia patients. Most importantly, natural antioxidants
are ubiquitous and very cheap whereas antioxidant supplements are free from the side effects
commonly encountered in iron chelation and chemotherapeutic treatments.
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